An essential part of our mission is to quickly develop human compatible organs at scale to ensure there is no organ shortage for those in need. We have a robust approach to developing human compatible organs that was meticulously designed for safety, efficacy, and efficiency.
Single Cell Cloning
Somatic Cell Nuclear / Embryo Transfer
We are a science-first team. To learn more, view our publications.
eGenesis has the potential to pioneer clinical studies for solid organ xenotransplantation. Our lead program is for Kidney Transplantation, which is currently under preclinical development. eGenesis has a platform technology that allows for a broad pipeline of applications. We are actively investigating additional indications such as islet cells, liver, heart, and lung as well as cell therapy.
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.
eGenesis Headquarters 300 Technology Square Suite 301 Cambridge, MA 02139